Search Result
Results for "
PPAR-γ Agonists
" in MedChemExpress (MCE) Product Catalog:
25
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-13956
-
|
U 72107
|
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
|
-
-
- HY-50935
-
|
CS-045
|
PPAR
Autophagy
Apoptosis
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Troglitazone is an orally active PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.
|
-
-
- HY-16995
-
|
Wy-14643
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
|
-
-
- HY-15655
-
|
|
PPAR
|
Neurological Disease
Metabolic Disease
|
|
GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .
|
-
-
- HY-14601
-
|
U 72107A; AD 4833
|
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
|
-
-
- HY-B0637
-
|
BM15075
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-N0246
-
|
|
LXR
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .
|
-
-
- HY-B0205
-
|
CV 11974
|
Angiotensin Receptor
PPAR
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
|
-
-
- HY-N0234
-
|
7-O-Methylbavachin; Bavachinin A
|
Amyloid-β
PPAR
HIF/HIF Prolyl-Hydroxylase
|
Inflammation/Immunology
Cancer
|
|
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
|
-
-
- HY-N6869
-
|
|
Antibiotic
PPAR
Bacterial
Fungal
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
|
-
-
- HY-B0287
-
|
|
PPAR
|
Metabolic Disease
|
|
Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ~500 μM for murine PPARα and PPARγ, and 55 μM, ~500 μM for human PPARα and PPARγ, respectively.
|
-
-
- HY-N2025
-
|
|
PPAR
Glycosidase
|
Metabolic Disease
|
|
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .
|
-
-
- HY-16086
-
|
DRF 2593; NN 2344
|
PPAR
|
Metabolic Disease
|
|
Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM for human PPARγ.
|
-
-
- HY-14817
-
|
PPM 204
|
PPAR
|
Metabolic Disease
|
|
Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα, PPARδ and PPARγ .
|
-
-
- HY-148351
-
|
|
PPAR
|
Cancer
|
|
BAY-0069 is a potent and selective PPARγ inverse agonist with an IC50 value of 6.3 nM and 24 nM for human PPARγ and mouse PPARγ. BAY-0069 can be used to research cancer .
|
-
-
- HY-120160
-
|
CP-86325
|
PPAR
|
Neurological Disease
Metabolic Disease
|
|
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
|
-
-
- HY-14792B
-
|
Efatutazone dihydrochloride; CS-7017 dihydrochloride; RS5444 dihydrochloride
|
PPAR
|
Cancer
|
|
Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
|
-
-
- HY-148352
-
|
|
PPAR
|
Cancer
|
|
BAY-4931 is a potent, covalent and selective PPARγ inverse-agonist with an IC50 of 0.17 nM .
|
-
-
- HY-14601R
-
|
U 72107A (Standard); AD 4833 (Standard)
|
Reference Standards
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone (hydrochloride) (Standard) is the analytical standard of Pioglitazone (hydrochloride). This product is intended for research and analytical applications. Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
|
-
-
- HY-110118
-
|
|
PPAR
|
Metabolic Disease
|
|
Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC50s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .
|
-
-
- HY-N9333
-
-
-
- HY-122235
-
-
-
- HY-14831
-
|
MBX 102; JNJ 39659100
|
PPAR
|
Metabolic Disease
|
|
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.
|
-
-
- HY-150308
-
|
|
PPAR
|
Cancer
|
|
SR10221, a noncovalent inverse agonist of PPARγ, represses downstream PPARγ target genes leading to growth inhibition in bladder cancer cell lines .
|
-
-
- HY-13956S1
-
|
|
Isotope-Labeled Compounds
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone-d4 (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .
|
-
-
- HY-144111
-
|
|
PPAR
|
Inflammation/Immunology
|
|
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC50=7.0 nM; PPARδ EC50=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC50=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .
|
-
-
- HY-17386S
-
-
-
- HY-B0637S
-
|
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-146480
-
|
|
PPAR
|
Cancer
|
|
PPARγ agonist 5 (Compound 1) is a potent and selective agonist of PPARγ. PPARγ agonist 5 has the potential for the research of cancer diseases .
|
-
-
- HY-116468
-
-
-
- HY-159944
-
|
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .
|
-
-
- HY-14792
-
|
Efatutazone; CS-7017; RS5444
|
PPAR
|
Cancer
|
|
Inolitazone a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
|
-
-
- HY-138007
-
|
|
ROR
PPAR
LXR
|
Metabolic Disease
Inflammation/Immunology
|
|
SR-1903 is an inverse agonist of RORγ and PPARγ (IC50 of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .
|
-
-
- HY-101292
-
|
|
PPAR
|
Metabolic Disease
|
|
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .
|
-
-
- HY-B0287R
-
|
|
Reference Standards
PPAR
|
Metabolic Disease
|
|
Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ~500 μM for murine PPARα and PPARγ, and 55 μM, ~500 μM for human PPARα and PPARγ, respectively.
|
-
-
- HY-178447
-
|
|
PPAR
Glutathione Peroxidase
SOD
TNF Receptor
Interleukin Related
NF-κB
|
Infection
Metabolic Disease
Endocrinology
|
|
PPARγ agonist 20 is a potent, orally active PPAR-γ agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes .
|
-
-
- HY-N0246R
-
|
|
Reference Standards
LXR
Bacterial
|
Metabolic Disease
Inflammation/Immunology
|
|
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .
|
-
-
- HY-146482
-
|
|
PPAR
|
Cancer
|
|
PPARγ agonist 6 (Compound 12) is a potent and selective agonist of PPARγ. PPARγ agonist 6 has the potential for the research of cancer diseases .
|
-
-
- HY-162320
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC50s of 3.98 and 15.42 μM against PPARγ and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .
|
-
-
- HY-B0205R
-
|
CV 11974 (Standard)
|
Reference Standards
Angiotensin Receptor
PPAR
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
|
-
-
- HY-50935S
-
-
-
- HY-116521
-
-
-
- HY-13956B
-
|
U 72107 potassium
|
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research .
|
-
-
- HY-B0205S
-
|
CV-11974-d4
|
Angiotensin Receptor
|
Others
|
|
Candesartan-d4 (CV-11974-d4) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).
|
-
-
- HY-14792C
-
|
Efatutazone hydrochloride hydrate; CS-7017 hydrochloride hydrate; RS5444 hydrochloride hydrate
|
PPAR
|
Cancer
|
|
Inolitazone hydrochloride hydrate (Efatutazone hydrochloride hydrate) is a novel PPARγ high-affinity agonist, with an EC50 value one-fiftieth that of Rosiglitazone (HY-17386), and shows no inhibitory effect on RIE cells that do not express PPARγ. Inolitazone hydrochloride hydrate can be used in the research of cancer .
|
-
-
- HY-105074
-
|
GI262570; GI262570X
|
PPAR
|
Metabolic Disease
|
|
Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
|
-
-
- HY-U00340
-
|
|
PPAR
|
Metabolic Disease
|
|
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
|
-
-
- HY-13956R
-
|
U 72107 (Standard)
|
Reference Standards
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
|
-
-
- HY-117422
-
|
11-Oxo-prosta-5Z,12E,14Z-trien-1-oic acid
|
PPAR
|
Cancer
|
|
CAY10410 (11-Oxo-prosta-5Z), a 15d-PGJ2 analog, is a potent PPARγ agonist. CAY10410 has the ability to activate PPARγ in human B cells without killing B lymphocytes .
|
-
-
- HY-14728S
-
|
Aleglitazar-d2; R1439-d2; RO0728804-d2
|
PPAR
|
Others
|
|
Deutaleglitazar (Aleglitazar-d2) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ) .
|
-
- HY-111775
-
|
|
PPAR
|
Metabolic Disease
|
|
LJ570 is a PPARα/PPARγ dual agonist with EC50s of 1.05 and 0.12 μM, respectively .
|
-
- HY-117761
-
|
|
PPAR
|
Metabolic Disease
Cancer
|
|
MHY908 is a potent dual agonist of PPARα and PPARγ . MHY908 also inhibits melanogenesis through inhibition of mushroom tyrosinase activity .
|
-
- HY-110022
-
|
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential .
|
-
- HY-113473
-
|
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
10-Nitrolinoleic acid is a potent peroxisome proliferator-activated receptor γ (PPARγ) agonist. 10-Nitrolinoleic acid competes with [ 3H]Rosiglitazone for binding to PPAR-γ, with an IC50 of 0.22 μM .
|
-
- HY-14831A
-
|
(+)-MBX 102; (+)-JNJ 39659100
|
PPAR
|
Metabolic Disease
|
|
(+)-Arhalofenate ((+)-MBX 102) is the less active enantiomer of Arhalofenate (HY-14831). Arhalofenate is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes .
|
-
- HY-138997
-
|
|
PPAR
|
Metabolic Disease
|
|
MBX-102 acid is a selective partial PPAR-γ agonist. MBX-102 acid binds highly to plasma proteins, mainly serum albumin. MBX-102 acid can be used to study type 2 diabetes .
|
-
- HY-120160A
-
|
CP 86325 Sodium
|
PPAR
|
Neurological Disease
Metabolic Disease
|
|
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
|
-
- HY-106181A
-
|
R-106056 hydrochloride
|
PPAR
|
Metabolic Disease
|
|
Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating PPARγ to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes .
|
-
- HY-146438
-
|
|
PPAR
|
Cancer
|
|
PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of PPARγ. PPARγ agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib .
|
-
- HY-146439
-
|
|
PPAR
|
Cancer
|
|
PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of PPARγ. PPARγ agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib .
|
-
- HY-160003
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC50 more than 10 μM for LPA3 receptor .
|
-
- HY-147511
-
|
|
PPAR
|
Others
|
|
PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of PPARγ. PPARγ agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC50, 4.34 μM) .
|
-
- HY-153982
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist 8 is an agonist of PPARγ. PPARγ agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC50 of 0.2 μM .
|
-
- HY-146731
-
|
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .
|
-
- HY-168719
-
|
|
PPAR
|
Inflammation/Immunology
|
|
PPARγ agonist 16 (Compound 4G) is the agonist for PPARγ, that competitively binds to LBD domain of PPARγ with IC50 of 1790 nM. PPARγ agonist 16 inhibits the ear swelling in mouse model, and exhibits anti-hyperglycemic in Streptozotocin (HY-13753)-induced mouse diabetes mellitus model .
|
-
- HY-146742
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist 2 is a potent PPARγ partial agonist and can be used for metabolic disease research .
|
-
- HY-169404
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist 15 (Compound 7c) is an agonist for PPARγ. PPARγ agonist 15 inhibits the expression of alpha-amylase (HPA) and alpha-glucosidase (HLAG) with IC50 of 28.35 µM and 26.21 µM. PPARγ agonist 15 enhances glucose uptake in the L6 myotube cell. PPARγ agonist 15 improves glucose homeostasis, insulin sensitivity, and lipid metabolism in rat Streptozotocin (HY-13753)-induced diabetes model .
|
-
- HY-176214
-
|
|
PPAR
COX
|
Metabolic Disease
|
|
PPARγ agonist 19 (Compound 5e) is a PPARγ agonist. PPARγ agonist 19 has an IC50 of 11.27 μM against COX-1 and an IC50 of 0.05 μM against COX-1. PPARγ agonist 19 increases glucose uptake in rat hemidiaphragm assay and is superior to pioglitazone (HY-13956). PPARγ agonist 19 alleviates hyperglycemia and insulin resistance in an in vivo model of type 2 diabetes in rats and protects against renal and lipidemia damage caused by metabolic dysfunction .
|
-
- HY-163294
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .
|
-
- HY-N6869R
-
|
|
Antibiotic
Reference Standards
PPAR
Bacterial
Fungal
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
|
-
- HY-154985
-
|
|
PPAR
Bombesin Receptor
ERK
|
Metabolic Disease
|
|
DSO-5a is a potent, selective, orally active BB3 agonist. DSO-5a is a representative DMAKO-00 derivative compound. DSO-5a upregulates ppar-γ activity through BB3 and activates ERK1/2 phosphorylation. DSO-5a can be used in diabetes-related research .
|
-
- HY-13956S
-
|
U 72107-d4
|
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone-d4 is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .
|
-
- HY-16086R
-
|
DRF 2593 (Standard); NN 2344 (Standard)
|
PPAR
Reference Standards
|
Metabolic Disease
|
|
Balaglitazone (Standard) is the analytical standard of Balaglitazone. This product is intended for research and analytical applications. Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM for human PPARγ.
|
-
- HY-118097
-
|
|
PPAR
|
Others
|
|
GW0072 is a partial agonist of PPARγ and does not directly bind to the AF-2 helix of PPARγ, resulting in specific partial receptor transcriptional activation properties .
|
-
- HY-108572
-
|
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC50=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ .
|
-
- HY-14792BR
-
|
Efatutazone dihydrochloride (Standard); CS-7017 dihydrochloride (Standard); RS5444 dihydrochloride (Standard)
|
PPAR
Reference Standards
|
Cancer
|
|
Inolitazone (dihydrochloride) (Standard) is the analytical standard of Inolitazone (dihydrochloride). This product is intended for research and analytical applications. Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
|
-
- HY-B0287S
-
|
|
PPAR
|
Metabolic Disease
|
|
Clofibrate-d4 is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.
|
-
- HY-148922
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC50 values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .
|
-
- HY-N2025R
-
|
|
Reference Standards
PPAR
Glycosidase
|
Metabolic Disease
|
|
Oroxin A (Standard) is the analytical standard of Oroxin A. This product is intended for research and analytical applications. Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .
|
-
- HY-13956C
-
|
(R)-U 72107
|
PPAR
|
Neurological Disease
|
|
(R)-Pioglitazone ((+)-pioglitazone) is the R enantiomer of Pioglitazone (HY-13956). (R)-Pioglitazone is an orally active and selective peroxisome proliferator-activated receptor (PPARγ) agonist with high affinity binding to the PPARγ ligand-binding domain. (R)-Pioglitazone can be used for the research of Alzheimer's disease .
|
-
- HY-50935R
-
|
CS-045 (Standard)
|
Reference Standards
PPAR
Autophagy
Apoptosis
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Troglitazone (Standard) is the analytical standard of Troglitazone. This product is intended for research and analytical applications. Troglitazone is an orally active PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.
|
-
- HY-W738533
-
|
U 72107A-d4; AD 4833-d4
|
Isotope-Labeled Compounds
PPAR
Ferroptosis
|
Cancer
|
|
Pioglitazone-d4 hydrochloride (U 72107A-d4; AD 4833-d4) is the deuterium labeled Pioglitazone hydrochloride (HY-14601). Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
|
-
- HY-123654
-
|
|
PPAR
|
Neurological Disease
|
|
L-796449 is a potent PPARγ agonist. L-796449 shows neuroprotective. L-796449 has the potential for the research of stroke .
|
-
- HY-107333
-
|
|
PPAR
|
Metabolic Disease
|
|
Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity .
|
-
- HY-B0637S1
-
|
BM15075-d4
|
Isotope-Labeled Compounds
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
- HY-121798
-
|
|
PPAR
|
Metabolic Disease
|
|
TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC50 values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes .
|
-
- HY-120542
-
|
|
PPAR
|
Metabolic Disease
|
|
SR 1824 is a non-agonist PPARγ ligand that blocks Cdk5-mediated phosphorylation. SR 1824 has anti-diabetic effects .
|
-
- HY-N0234R
-
|
7-O-Methylbavachin (Standard); Bavachinin A (Standard)
|
Amyloid-β
Reference Standards
PPAR
HIF/HIF Prolyl-Hydroxylase
|
Inflammation/Immunology
|
|
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
|
-
- HY-16995R
-
|
Wy-14643 (Standard)
|
PPAR
Reference Standards
|
Metabolic Disease
Inflammation/Immunology
|
|
Pirinixic acid (Standard) is the analytical standard of Pirinixic acid. This product is intended for research and analytical applications. Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
|
-
- HY-B0637R
-
|
BM15075 (Standard)
|
Reference Standards
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
- HY-U00450R
-
-
- HY-180890
-
-
- HY-181233
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ agonist-22 is a PPARγ agonist. PPARγ agonist-22 promotes cellular glucose uptake. PPARγ agonist-22 reduces lipid accumulation in adipocytes. PPARγ agonist-22 can be used in the research of type 2 diabetes .
|
-
- HY-181896S
-
|
|
PPAR
|
Inflammation/Immunology
|
|
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC50 of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis .
|
-
- HY-180398
-
|
|
PPAR
PGC-1α
|
Metabolic Disease
|
|
PA-082 is a selective PPAR-γ modulator that functions as a partial agonist. PA-082 causes partial recruitment of SRC1, TIF2, SRC3 and full recruitment of PGC1-α to PPAR-γ ligand-binding domain. PA-082 prevents triglyceride accumulation during de novo adipogenesis and antagonizes Rosiglitazone (HY-17386)-induced lipid accumulation. PA-082 potentiates insulin-stimulated glucose uptake in adipocytes and protects against TNFα-induced insulin resistance. PA-082 can be used for the research of type 2 diabetes .
|
-
- HY-173166
-
|
|
PPAR
|
Cancer
|
|
PPARγ agonist 17 (Compound C1) is a PPARγ agonist. PPARγ agonist 17 enhances PPARγ activity and blocks the cell cycle in G2/M phase, inhibits cell migration and induces apoptosis in HT-29 cells. PPARγ agonist 17 has a broad spectrum anti-proliferative activity in cancer cells with relatively low toxicity in normal cells which cannot cross the blood-brain barrier .
|
-
- HY-123974
-
|
|
PPAR
|
Metabolic Disease
|
|
BR101549 is a non-TZD agonist of PPARγ. BR101549 activates PPARγ to the level of Pioglitazone in vitro. BR101549 can control blood glucose level in mouse model. BR101549 can be studied in anti-diabetic research .
|
-
- HY-122222
-
|
|
PPAR
|
Others
|
|
MRL20 is a PPARγ constitutive and allosteric agonist. MRL20 enhances the interaction between PPARγ and the co-activating peptide of TRAP220, with its EC50 being 10 nM. Even after being covalently blocked in the constitutive pocket by GW9662 (HY-16578) or T0070907 (HY-13202), MRL20 can still strengthen the interaction between PPARγ and TRAP220, with EC50 values of 176 and 440 nM respectively. MRL20 fails to completely inhibit its cell activation effect. MRL20 can be used to study the allosteric regulatory mechanism of PPARγ .
|
-
- HY-N18020
-
-
- HY-101292R
-
|
|
PPAR
Reference Standards
|
Metabolic Disease
|
|
FK614 (Standard) is the analytical standard of FK614 (HY-101292). This product is intended for research and analytical applications. FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .
|
-
- HY-16421
-
|
(-)-DRF 2725; NNC 61-0029
|
PPAR
|
Metabolic Disease
|
|
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.
|
-
- HY-U00450
-
|
|
PPAR
NF-κB
|
Inflammation/Immunology
Cancer
|
|
4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a PPARγ agonist, and inhibtis NF-κB activity, used for cancer and inflammation research.
|
-
- HY-119197
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARα/γ/δ agonist 1 (Compound 2) is a potent PPARα/γ/δ agonist, with an IC50 of 70 nM for PPARγ. PPARα/γ/δ agonist 1 can be used for the research of type 2 diabetes .
|
-
- HY-B0637S2
-
|
BM15075-13C6
|
Isotope-Labeled Compounds
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
Bezafibrate- 13C6 (BM15075- 13C6) is 13C labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
- HY-20019
-
|
|
PPAR
|
Metabolic Disease
|
|
L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.
|
-
- HY-160161
-
|
|
PPAR
|
Cancer
|
|
BAY-5094 is a PPAR gamma (PPARG) inverse agonist. BAY-5094 has oral activity. BAY-5094 can be used in the research of luminal bladder cancer .
|
-
- HY-13861
-
|
|
PPAR
|
Cardiovascular Disease
|
|
GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.
|
-
- HY-106181R
-
|
R-106056 (Standard)
|
Reference Standards
PPAR
|
Metabolic Disease
|
|
Rivoglitazone (Standard) is the analytical standard of Rivoglitazone (HY-106181). This product is intended for research and analytical applications. Rivoglitazone is a thiazolidinedione-derivative PPARγ agonist for the research of type 2 diabetes mellitus.
|
-
- HY-N7624
-
|
3-Oxoolean-12-en-28-oic acid methyl ester
|
PPAR
|
Cancer
|
|
Methyl oleanonate is a natural triterpene PPARγ agonist isolated from the species of Pistacia lentiscus var. Chia . Methyl oleanonate is a modified oleanolic acid derivative with anti-cancer effects .
|
-
- HY-W341997
-
|
|
PPAR
|
Metabolic Disease
|
|
9-Octadecynoic acid is a DNA binding agent with a dissociation constant of 1.8 mM. 9-Octadecynoic acid is also an agonist for peroxisome proliferator-activated receptor γ (PPARγ) .
|
-
- HY-163547
-
|
|
PPAR
|
Inflammation/Immunology
|
|
PPAR agonist 5 (compound 4b) is a potent PPAR agonist with EC50 values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect .
|
-
- HY-100428
-
|
MCC-555; Isaglitazone
|
PPAR
|
Metabolic Disease
|
|
Netoglitazone (MCC-555) is an orally active PPARγ ligand with an EC50 of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of PPARγ as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus .
|
-
- HY-106266
-
|
Carfloglitazar
|
PPAR
|
Metabolic Disease
|
|
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC50s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.
|
-
- HY-124907
-
|
OMS-403
|
PPAR
|
Neurological Disease
|
|
AI 3-25755 (OMS-403) is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. AI 3-25755 can be used for research on opioid abuse and smoking cessation .
|
-
- HY-173443
-
-
- HY-10678
-
|
|
PPAR
|
Cardiovascular Disease
|
|
BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
|
-
- HY-19937
-
|
|
PPAR
|
Metabolic Disease
|
|
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
- HY-N0163
-
-
- HY-106266B
-
|
Carfloglitazar sodium
|
PPAR
|
Metabolic Disease
|
|
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC50s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.
|
-
- HY-19937A
-
|
|
PPAR
|
Metabolic Disease
|
|
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
- HY-19394
-
|
|
PPAR
|
Metabolic Disease
|
|
CLX-0921 is an orally active PPARγ agonist with an IC50 of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes .
|
-
- HY-143239
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARα/γ agonist 1 (compound 5b) is a potent and dual PPARα/γ partial agonist with EC50 values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research .
|
-
- HY-127003
-
|
|
PPAR
TRP Channel
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Neoambrosin is a sesquiterpene lactone. Neoambrosin acts as a partial agonist of PPARγ and TRPA1 receptors, with no carbonic anhydrase inhibitory activity. Neoambrosin can be used in research on hypoglycemia, analgesia, anti-inflammation and anticancer effects .
|
-
- HY-114853
-
|
|
PPAR
|
Metabolic Disease
|
|
BVT.13 is an orally active and selective PPARγ agonist with a maximal efficacy similar to that of Rosiglitazone (HY-17386). In addition, BVT.13 exhibits antidiabetic activity in ob/ob mice .
|
-
- HY-130289
-
|
4-Hydroxy docosahexaenoic acid; (±)4-HDoHE
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
(±)4-HDHA (4-Hydroxy docosahexaenoic acid) is an autoxidation product of Docosahexaenoic acid (HY-B2167) (DHA). (±)4-HDHA is a PPARγ agonist, antidiabetic and anti-inflammatory agent .
|
-
- HY-105074R
-
|
GI262570 (Standard); GI262570X (Standard)
|
Reference Standards
PPAR
|
Metabolic Disease
|
|
Farglitazar (Standard) is the analytical standard of Farglitazar (HY-105074). This product is intended for research and analytical applications. Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
|
-
- HY-119248
-
|
MK-0767
|
PPAR
|
Metabolic Disease
|
|
KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.
|
-
- HY-163443
-
|
|
PPAR
|
Others
|
|
PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC50s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy .
|
-
- HY-14728
-
|
R1439; RO0728804
|
PPAR
|
Metabolic Disease
|
|
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes .
|
-
- HY-128344
-
|
|
PARP
Apoptosis
|
Metabolic Disease
|
|
BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC50 value of 0.28 μM and Amax ratio of 98% .
|
-
- HY-107333S
-
|
|
Isotope-Labeled Compounds
PPAR
|
Metabolic Disease
|
|
Cinoxate-d3 is deuterium labeled Cinoxate. Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity .
|
-
- HY-139172
-
|
|
PPAR
|
Metabolic Disease
|
|
MD001 is a PPARα/γ dual agonist and can increase the transcriptional activity of PPARα and PPARγ. MD001 enhances the expression of genes related to β-oxidation and fatty acid and glucose uptake .
|
-
- HY-113631
-
|
|
PPAR
|
Neurological Disease
Metabolic Disease
|
|
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with Ki values of 19 nM and EC50 values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .
|
-
- HY-118514
-
|
|
PPAR
|
Metabolic Disease
|
|
CAY10514 is an aromatic of 8(S)-HETE. CAY10514 acts as a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ with IC50 of 0.173 and 0.642 μM, respectively .
|
-
- HY-161999
-
|
|
Glycosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
α-Glucosidase-IN-73 (compound 16b) is an α-Glucosidase inhibitor with IC50 of 0.158 μM. α-Glucosidase-IN-73 can activate PPAR γ. α-Glucosidase-IN-73 can be used in anti-diabetic and anti-inflammatory studies .
|
-
- HY-170581
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ/δ modulator 2 (Compound 3h) is a PPARγ agonist and PPARδ antagonist. The Ki values for PPARγ and PPARδ are 2.8 μM and 43 nM, respectively. PPARγ/δ modulator 2 significantly enhances the production of Adiponectin and promotes adipogenic differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs). PPARγ/δ modulator 2 can be used in the study of metabolic disorders associated with hypoadiponectinemia .
|
-
- HY-133559
-
|
|
PPAR
|
Metabolic Disease
|
|
VSP-77 is an orally active PPARγ agonist. VSP-77 selectively upregulates the expression of insulin sensitivity-related genes (Glut4 and Adiponectin) by inhibiting CDK5-mediated phosphorylation of PPARγ at Ser-273. VSP-77 significantly improves glucose tolerance, reduces fasting blood glucose and insulin levels in high-fat diet (HFD)-induced diabetic mouse models. VSP-77 can be used for the study of diabetes .
|
-
- HY-N7687
-
|
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC50 of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation .
|
-
- HY-15027
-
-
- HY-178958
-
|
|
PPAR
Adenosine Receptor
Fatty Acid Synthase (FASN)
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/
Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes .
|
-
- HY-172792
-
|
|
PPAR
|
Metabolic Disease
|
|
PPAR agonist 6 (compound 5a) is an agonist of PPAR with EC50 values of 3.6 μM, 2.6 μM, and 2.7 μM for PPARα, PPARβ/δ, and PPARγ, respectively. PPAR agonist 6 represses the transactivation of the TNFα-dependent NF-κB-driven reporter in L929 cells .
|
-
- HY-100428R
-
|
MCC-555 (Standard); Isaglitazone (Standard)
|
Reference Standards
PPAR
|
Metabolic Disease
|
|
Netoglitazone (Standard) is the analytical standard of Netoglitazone (HY-100428). This product is intended for research and analytical applications. Netoglitazone (MCC-555) is an orally active PPARγ ligand with an EC50 of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of PPARγ as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus .
|
-
- HY-113827
-
|
|
Nuclear Hormone Receptor 4A/NR4A
|
Inflammation/Immunology
|
|
THPN is a potent Nur77 agonist. THPN specifically binds the LBD of Nur77 (TR3) but not that of retinoic acid receptor α and PPARγ with a Kd of 270 nM. THPN leads to Nur77 translocation to the mitochondria to induce autophagic cell death in melanoma .
|
-
- HY-106278
-
|
|
PPAR
|
Metabolic Disease
|
|
GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .
|
-
- HY-108523
-
|
UVI 2112
|
RAR/RXR
|
Metabolic Disease
|
|
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .
|
-
- HY-13928
-
-
- HY-111254
-
|
|
PPAR
NF-κB
JNK
|
Inflammation/Immunology
|
|
GQ-16 is an orally active PPARγ partial agonist with an IC50 of 1.84 μM and a Ki of 160 nM against human PPARγ. GQ-16 inhibits Cdk5-mediated Ser-273 phosphorylation. GQ-16 improves insulin sensitivity and glucose tolerance in obese and diabetic mice. GQ-16 also exhibits certain cytotoxicity against tumor cells. GQ-16 can be used in research related to obesity, diabetes and cancer .
|
-
- HY-111616
-
|
|
PPAR
Angiotensin Receptor
|
Cardiovascular Disease
Others
|
|
GSK1820795A, as a telmisartan analog, is a selective hGPR132a antagonist. GSK1820795A blocks activation of yeast cells expressing hGPR132a by N-acylamides . GSK1820795A is also a angiotensin II antagonists and partial PPARγ agonists (compound 38) .
|
-
- HY-15027S
-
-
- HY-N0163R
-
-
- HY-17386B
-
-
- HY-N6642
-
|
|
PPAR
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active PPARγ agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects .
|
-
- HY-118788
-
-
- HY-17386A
-
-
- HY-151963
-
|
|
PPAR
Glucocorticoid Receptor
|
Metabolic Disease
|
|
PPARγ/GR modulator 1 is an orally active dual agonist of PPARγ and glucocorticoid receptor (GR), with Kis of 3.3 and 33.6 μM, respectively. PPARγ/GR modulator 1 can be used for the research of metabolic diseases, such as diabetes .
|
-
- HY-168485
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARα/δ agonist 3 (Compound 8) is the orally active agonist for PPAR, that activates PPARα, PPARδ and PPARγ with EC50s of 5.6, 3.4 and 1278 nM, respectively. PPARα/δ agonist 3 exhibits anticholestatic activity in mouse ANIT- or CDCA (HY-76847)-induced cholestatic liver disease models .
|
-
- HY-13861R
-
|
|
PPAR
|
Cardiovascular Disease
|
|
GW7647 (Standard) is the analytical standard of GW7647. This product is intended for research and analytical applications. GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.
|
-
- HY-117727A
-
|
MIN-102 hydrochloride; Hydroxypioglitazone hydrochloride
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone hydrochloride, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone hydrochloride can be used in the study of neuroinflammatory and neurodegenerative diseases .
|
-
- HY-112813
-
-
- HY-124581
-
|
|
PPAR
|
Metabolic Disease
|
|
DS-6930 is a potent and selective agonist of PPARγ, with an EC50 of 41 nM. DS-6930 could robust reduce plasma glucose (PG), and with fewer PPARγ-related adverse effects than Rosiglitazone. DS-6930 can be used for the research of diabetes .
|
-
- HY-117727
-
|
MIN-102; Hydroxypioglitazone
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .
|
-
- HY-134997
-
|
4-oxo DHA
|
PPAR
|
Cancer
|
|
4-oxo Docosahexaenoic acid (4-oxo DHA) is a putative metabolite of Docosahexaenoic acid (HY-B2167) with antiproliferative and PPARγ agonist activity. It inhibits the growth of several triple negative breast cancer cell lines (MCF-10F, trMCF, bsMCF, MDA-MB-231, and BT549) at 50-100 μM, however it increased proliferation of MCF-7 cells. 4-oxo DHA binds covalently to PPARγ and activates gene transcription in luciferase reporter assays and in dendritic cells with EC50 values of approximately 8-16 μM.
|
-
- HY-19848
-
|
LBM-642
|
PPAR
|
Metabolic Disease
|
|
Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research .
|
-
- HY-19937S1
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Saroglitazar-d4 is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d4 is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
- HY-15027S2
-
|
Mesalamine-13C6; 5-ASA-13C6; Mesalazine-13C6
|
PPAR
PAK
NF-κB
Endogenous Metabolite
|
Inflammation/Immunology
|
|
5-Aminosalicylic acid- 13C6 is the 13C labeled 5-Aminosalicylic Acid . 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
- HY-15027S1
-
-
- HY-19394A
-
|
|
PPAR
|
Metabolic Disease
|
|
(E)-CLX-0921 is the E-isomer of CLX-0921 (HY-19394). CLX-0921 is an orally active PPARγ agonist with an IC50 of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes .
|
-
- HY-121671
-
|
|
RAR/RXR
|
Neurological Disease
|
|
TBTC is a selective agonist with the activity of improving behavioral deficits in Alzheimer's disease model mice. TBTC can effectively activate the heterodimerization of RXRα with LXRα or PPARγ. TBTC stimulates the expression of apoE, ABCA1, and ABCG1 genes and reduces Aβ content in cells and animal models .
|
-
- HY-20019R
-
|
|
PPAR
|
Metabolic Disease
|
|
L-165041 (Standard) is the analytical standard of L-165041. This product is intended for research and analytical applications. L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.
|
-
- HY-106266R
-
|
Carfloglitazar (Standard)
|
Reference Standards
PPAR
|
Metabolic Disease
|
|
Chiglitazar (Standard) is the analytical standard of Chiglitazar (HY-106266). This product is intended for research and analytical applications. Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC50s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.
|
-
- HY-19522A
-
|
MBX-8025 sodium; RWJ-800025 sodium
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .
|
-
- HY-19522
-
|
MBX-8025; RWJ-800025
|
PPAR
|
Metabolic Disease
|
|
Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .
|
-
- HY-162578
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARα/γ agonist 4 (Compound (S)-7) is an orally active dual potent agonist of PPARα and PPARγ, with EC50 values of 0.061 μM and 1.42 μM respectively. PPARα/γ agonist 4 acts through an insulin-independent mechanism and exhibits mitochondrial pyruvate carrier inhibition and anti-diabetic properties. PPARα/γ agonist 4 is expected to be used in research for dyslipidemic type 2 diabetes .
|
-
- HY-Y1624
-
|
ADDP; SR 4077
|
Free Fatty Acid Receptor
PPAR
|
Metabolic Disease
|
|
1,1'-(Azodicarbonyl)-dipiperidine (ADDP) can be used in the condensation reaction of alcohols with acidic compounds. 1,1'-(Azodicarbonyl)-dipiperidine can also be used in the synthesis of GPR120 agonists with antidiabetic activity, as well as the synthesis of triple agonists for PPARα, PPARγ, and PPARδ. 1,1'-(Azodicarbonyl)-dipiperidine can be used in metabolic disease research .
|
-
- HY-115357
-
|
|
PPAR
|
Metabolic Disease
|
|
BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC50 of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides .
|
-
- HY-116699
-
|
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions .
|
-
- HY-N6641
-
|
|
Keap1-Nrf2
PPAR
|
Inflammation/Immunology
Cancer
|
|
Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and PPARγ agonist .
|
-
- HY-17386
-
-
- HY-121900
-
|
|
PPAR
|
Metabolic Disease
Endocrinology
|
|
LT175, a dual PPARα/γ ligand, is an orally active partial agonist against PPARγ(hPPARα:EC50=0.22 μm; mPPARα:EC50=0.26 μm; hPPARγ:EC50=0.48 μm). LT175 interacts with PPARγ and affects the recruitment of the coregulators cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1). LT175 interacts with PPARγ in a hydrophobic region called “diphenyl pocket”. LT175 has potent insulin-sensitizing effects and reduced adipogenic properties .
|
-
- HY-19522B
-
|
MBX-8025 (lysine); RWJ-800025 (lysine)
|
PPAR
|
Metabolic Disease
|
|
Seladelpar (MBX-8025) lysine is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar lysine shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar lysine can be used for the study of primary biliary cholangitis .
|
-
- HY-10678R
-
|
|
Reference Standards
PPAR
|
Cardiovascular Disease
|
|
BMS-687453 (Standard) is the analytical standard of BMS-687453 (HY-10678). This product is intended for research and analytical applications. BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
|
-
- HY-128872
-
|
EHP-101; VCE-004.8
|
PPAR
Cannabinoid Receptor
HIF/HIF Prolyl-Hydroxylase
|
Metabolic Disease
Inflammation/Immunology
|
|
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity .
|
-
- HY-17386AR
-
|
BRL 49653 hydrochloride (Standard)
|
PPAR
TRP Channel
Autophagy
Ferroptosis
Apoptosis
Reference Standards
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Rosiglitazone (hydrochloride) (Standard) is the analytical standard of Rosiglitazone (hydrochloride). This product is intended for research and analytical applications. Rosiglitazone (BRL 49653) hydrochloride is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone hydrochloride is a TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone hydrochloride can be used in the research of obesity and diabetes, senescence, ovarian cancer .
|
-
- HY-17386S1
-
-
- HY-14928
-
-
- HY-17386R
-
-
- HY-15027R
-
|
Mesalamine (Standard); 5-ASA (Standard); Mesalazine (Standard)
|
Reference Standards
PPAR
PAK
NF-κB
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
5-Aminosalicylic Acid (Standard) is the analytical standard of 5-Aminosalicylic Acid. This product is intended for research and analytical applications. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
|
-
- HY-13928R
-
-
- HY-173217
-
|
|
PPAR
Phosphatase
|
Cardiovascular Disease
Metabolic Disease
|
|
PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia .
|
-
- HY-108523R
-
|
UVI 2112 (Standard)
|
Reference Standards
RAR/RXR
|
Metabolic Disease
|
|
LG100754 (Standard) is the analytical standard of LG100754 (HY-108523). This product is intended for research and analytical applications. LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .
|
-
- HY-106278R
-
|
|
Reference Standards
PPAR
|
Metabolic Disease
|
|
GW 590735 (Standard) is the analytical standard of GW 590735 (HY-106278). This product is intended for research and analytical applications. GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .
|
-
- HY-128932
-
|
MT-141
|
Antibiotic
Bacterial
PPAR
Prostaglandin Receptor
PTEN
Akt
mTOR
|
Infection
Cardiovascular Disease
Endocrinology
|
|
Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model .
|
-
- HY-19425
-
|
|
PPAR
|
Metabolic Disease
|
|
NS-220 is an orally active PPARα agonist with high subtype selectivity, with EC50 values of 1.9×10 -8 M, 9.6×10 -6 M and >10 -4 M for PPARα, PPAR γ and PPARδ, respectively. NS-220 is used in the research for hyperlipidemia or metabolic disorders in type-2 diabetes .
|
-
- HY-183318
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARα/δ agonist 4 is a potent orally active and selective dual peroxisome proliferator-activated receptor (PPAR) α/δ agonist with EC50s of 0.36 and 1.31 nM, respectively. PPARα/δ agonist 4 exhibits >123-fold selectivity over PPARγ (EC50 = 160.84 nM). PPARα/δ agonist 4 upregulates expression of downstream fatty acid oxidation genes PDK4, CPT1A, and ACADVL. PPARα/δ agonist 4 can be used for the research of metabolic dysfunction-associated steatohepatitis .
|
-
- HY-14928A
-
-
- HY-119311
-
|
|
PPAR
|
Metabolic Disease
|
|
Pioglitazone ketone is an active metabolite of the PPARγ agonist Pioglitazone (HY-13956). Formation of pioglitazone ketone occurs primarly through cytochrome P450 (CYP) isoform CYP2C8-mediated metabolism of pioglitazone. Pioglitazone ketone (100 mg/kg in the diet) reduces blood glucose levels in a KKAy mouse model of type 2 diabetes.
|
-
- HY-19522R
-
|
MBX-8025 (Standard); RWJ-800025 (Standard)
|
PPAR
Reference Standards
|
Metabolic Disease
|
|
Seladelpar (Standard) is the analytical standard of Seladelpar. This product is intended for research and analytical applications. Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .
|
-
- HY-117727S
-
|
MIN-102-d4; Hydroxypioglitazone-d4
|
Isotope-Labeled Compounds
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Leriglitazone-d4 (MIN-102-d4; Hydroxypioglitazone-d4) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .
|
-
- HY-15027S3
-
|
Mesalamine-d3 disodium; 5-ASA-d3 disodium; Mesalazine-d3 disodium
|
PPAR
NF-κB
Endogenous Metabolite
PAK
Isotope-Labeled Compounds
|
Inflammation/Immunology
|
|
5-Aminosalicylic acid-d3 disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
|
-
- HY-N6641R
-
|
|
Reference Standards
Keap1-Nrf2
PPAR
|
Inflammation/Immunology
Cancer
|
|
Monascin (Standard) is the analytical standard of Monascin. This product is intended for research and analytical applications. Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and PPARγ agonist .
|
-
- HY-N15574
-
|
|
LXR
Bacterial
PPAR
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Saringosterol is an orally active steroid found in Sargassum muticum. Saringosterol is a LXR agonist. Saringosterol can lower cholesterol levels and inhibit the mRNA and protein expression of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT enhancer-binding protein α (C/EBPα). Saringosterol has anti-obesity, anti-atherosclerosis, anti-Mycobacterium tuberculosis and anti-depressant activities .
|
-
- HY-W011220
-
|
ADD-3878; U-63287
|
PPAR
|
Cardiovascular Disease
Cancer
|
|
Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells .
|
-
- HY-120327
-
KY-226
2 Publications Verification
|
Phosphatase
|
Neurological Disease
Metabolic Disease
|
|
KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury .
|
-
- HY-147757
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ/δ modulator 1 (compound 3e) is a potent PPAR modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with Ki values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC50 of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively .
|
-
- HY-119790
-
|
|
PPAR
|
Metabolic Disease
|
|
Palmitoyllactic acid is a long-chain fatty acid with lipogenic activity. Palmitoyllactic acid can induce a brown fat-like phenotype in 3T3-L1 cells. Palmitoyllactic acid enhances the expression of a variety of brown/beige cell-specific genes, such as Prdm16 and Pgc1a. Palmitoyllactic acid acts similarly to PPARγ agonists, significantly enhancing adipogenesis in the presence of dexamethasone. Palmitoyllactic acid can be used in obesity research .
|
-
- HY-A0087
-
|
|
Environmental Pollutants
PPAR
Estrogen Receptor/ERR
Biochemical Assay Reagents
Cytochrome P450
|
Others
|
|
Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes .
|
-
- HY-W010983
-
SC-236
2 Publications Verification
|
COX
PPAR
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
SC-236 is an orally active COX-2 specific inhibitor (IC50 = 10 nM) and a PPARγ agonist. SC-236 suppresses activator protein-1 (AP-1) through c-Jun NH2-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model .
|
-
- HY-W010983R
-
-
- HY-N7043
-
|
|
Apoptosis
PPAR
NF-κB
p38 MAPK
ERK
Androgen Receptor
|
Inflammation/Immunology
Cancer
|
|
Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity [1][2][3].
|
-
- HY-118249
-
|
|
PPAR
|
Neurological Disease
|
GSK 1997132B is a benzimidazole-based PPARγ partial agonist that can cross the blood-brain barrier with a pEC50 value of 8.0. GSK 1997132B has no significant effect on PPARα/δ. GSK 1997132B improves the problem of high blood clearance rate of earlier compounds, avoiding side effects such as weight gain and edema. GSK 1997132B can be used for research on Alzheimer's disease .
|
-
- HY-N10361
-
|
|
RAR/RXR
PPAR
Aldose Reductase
|
Cancer
|
|
Drupanin is an orally active and selective AKR1C3 enzyme inhibitor and an RXRα agonist with an EC50 value of 4.8 μM, which is found in green propolis. Drupanin also activates PPARγ moderately. Drupanin induces adipogenesis and elevates aP2 mRNA levels in 3T3-L1 fibroblasts Drupanin has the potential for the research of breast and prostate cancers .
|
-
- HY-17444
-
|
|
PPAR
|
Metabolic Disease
Cancer
|
|
Tesaglitazar is a dual-target PPARα/γ agonist with an EC50 of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .
|
-
- HY-128932R
-
|
MT-141 (Standard)
|
Reference Standards
Antibiotic
Bacterial
PPAR
Prostaglandin Receptor
PTEN
Akt
mTOR
|
Infection
Cardiovascular Disease
Endocrinology
|
|
Cefminox (sodium) (MT-141) (Standard) is the analytical standard of Cefminox (sodium). This product is intended for research and analytical applications. Cefminox sodium is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model .
|
-
- HY-15027S4
-
|
5-ASA-d7; Mesalamie-d7; Mesalazie-d7
|
Isotope-Labeled Compounds
PPAR
PAK
Endogenous Metabolite
NF-κB
|
Inflammation/Immunology
Cancer
|
|
5-Aminosalicylic acid-d7 (5-ASA-d7; Mesalamie-d7; Mesalazie-d7) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .
|
-
- HY-171793
-
|
|
PPAR
|
Metabolic Disease
|
|
DN-108, a thiazolidinedione derivative, is an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic effects. DN-108 improves hyperglycemia, hypertriglyceridemia and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increasing 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity. DN-108 is promising for research of type 2 diabetes .
|
-
- HY-N7043R
-
|
|
Reference Standards
Apoptosis
PPAR
NF-κB
p38 MAPK
ERK
Androgen Receptor
|
Inflammation/Immunology
Cancer
|
|
Isosilybin A (Standard) is the analytical standard of Isosilybin A (HY-N7043). Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity [1][2][3].
|
-
- HY-101676
-
|
NID 525
|
Leukotriene Receptor
PPAR
Cytochrome P450
|
Metabolic Disease
|
|
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 µM.
|
-
- HY-121746
-
|
|
PPAR
Calcium Channel
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
|
|
GW7845 is an orally active non-thiazolidinedione, tyrosine-derived PPARγ agonist. GW7845 is effective at inhibiting voltage-dependent calcium channels (VDCC) and relaxing pressurized arteries with IC50 of 3 μM by using Ba 2+ as the charge carrier through VDCC. GW7845-induced apoptosis is mitochondria- and apoptosome-dependent. GW7845 induces rapid mitochondrial membrane depolarization and release of cytochrome c in primary pro-B cells and BU-11 cells .
|
-
- HY-114520
-
|
|
Monoamine Oxidase
Mitochondrial Metabolism
Apoptosis
Reactive Oxygen Species (ROS)
|
Neurological Disease
Metabolic Disease
|
|
TT01001 is a selective and orally active mitoNEET agonist and a monoamine oxidase B (MAO-B) inhibitor (IC50 = 8.84 μM). TT01001 does not activate PPARγ but interacts with MitoNEET. TT01001 attenuates oxidative stress and neuronal apoptosis by preventing mitoNEET-mediated mitochondrial dysfunction. TT01001 improves type II diabetes and ameliorates mitochondrial function of mice. TT01001 can used for the studies of type II diabetes and neurological disorders .
|
-
- HY-W654296
-
|
|
Isotope-Labeled Compounds
PPAR
Cytochrome P450
Biochemical Assay Reagents
Estrogen Receptor/ERR
|
Others
|
|
Octocrylene- 13C3 is the 13C-labeled Octocrylene (HY-A0087). Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes .
|
-
- HY-106181
-
|
R-106056
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
Rivoglitazone (R-106056) is an orally active, selective PPARγ agonist with an EC50 of 0.22 μM for hPPARγ. Rivoglitazone regulates fatty acid storage and uptake, glucose homeostasis, and cardiac glucose/fatty acid metabolism. Rivoglitazone reduces levels of hyperglycemia, hyperinsulinemia, and hypertriglyceridemia, decreases hepatic glucose production, and accelerates plasma triglyceride clearance. Rivoglitazone induces a reduction in glycated hemoglobin A1C, while causing peripheral edema and weight gain. Rivoglitazone can be used in research related to type 2 diabetes .
|
-
- HY-168049
-
|
|
PPAR
Akt
|
Metabolic Disease
|
|
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .
|
-
- HY-179580
-
|
|
PPAR
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
EL244 is a dua Autotaxin (ATX) (IC50 = 50 nM) inhibitor and PPARγ (IC50 = 1.3 μM; Kd = 1.3 μM) agonist. EL244 demonstrates low cytotoxicity in human HepG2 cells (EC50 = 81.2 μM) with minimal inhibition of the cardiac hERG potassium channel (12% at 25 μM). EL244 significantly reduces pulmonary Lysophosphatidic Acid (LPA) levels, attenuates fibrosis, and restores respiratory function with limited systemic absorption in vivo. EL244 can be used for idiopathic pulmonary fibrosis and interstitial lung disease (ILD) research .
|
-
- HY-162713
-
|
|
EGFR
PI3K
PPAR
|
Cancer
|
|
MTX-531 is an oral drug that inhibits EGFR (with an IC50 of 14.7 nM) and PI3K (with IC50 values of 6.4, 233, 8.3, and 1.1 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ respectively), and it has anti-tumor effects. MTX-531 also acts as a weak agonist of PPARγ, with an IC50 of 2.5 µM, helping to alleviate hyperglycemia induced by PI3K inhibitors .
|
-
- HY-143704S
-
|
Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride
|
PPAR
NF-κB
PAK
|
Metabolic Disease
|
|
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
- HY-139408
-
|
17-Oxo-DHA; 17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-DHA
|
PPAR
Keap1-Nrf2
|
Metabolic Disease
|
|
17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid (17-Oxo-DHA) is a metabolite of lipoxygenase-mediated oxidation of DHA. 17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid is a PPARγ agonist and activates a Nrf2 dependent antioxidant reaction .
|
-
- HY-173115
-
|
|
COX
Lipoxygenase
Interleukin Related
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .
|
-
- HY-15697
-
TUG-770
3 Publications Verification
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TUG-770 is a potent, selective and orally active GPR40/FFA1 agonist with an EC50 of 6 nM for human FFA1. TUG-770 shows a high selectivity for FFA1 over FFA2, FFA3, FFA4, PPARγ, other receptors, transporters, and enzymes. TUG-770 can be uesd for type 2 diabetes research . TUG-770 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-108568
-
|
15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2
|
PPAR
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM .
|
-
- HY-148418
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TUG-499 is a selective free fatty acid receptor 1 (FFAR1 or GPR40) (Free Fatty Acid Receptor) agonist with a pEC50 of 7.39. TUG-499 exhibits >100-fold selectivity over the related receptors FFA2, FFA3, and the nuclear receptor PPARγ and other diverse receptors, ion channels, and transporters. TUG-499 can be used for the research of type 2 diabetes . TUG-499 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-12557
-
|
γ-Glu-Val
|
Endogenous Metabolite
CaSR
Wnt
TNF Receptor
Interleukin Related
PPAR
β-catenin
|
Inflammation/Immunology
|
|
γ‑Glutamylvaline (γ-Glu-Val) is a calcium‑sensing receptor (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1 and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation .
|
-
- HY-101676R
-
|
NID 525 (Standard)
|
Leukotriene Receptor
Reference Standards
PPAR
Cytochrome P450
|
Metabolic Disease
|
|
RG-12525 (Standard) is the analytical standard of RG-12525 (HY-101676). This product is intended for research and analytical applications. RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 μM.
|
-
- HY-U00425
-
|
|
Ligands for Target Protein for PROTAC
Estrogen Receptor/ERR
|
Metabolic Disease
Cancer
|
|
PROTAC ERRα ligand 1 is a PROTAC target protein ligand. PROTAC ERRα ligand 1 is an orally active ERRα inverse agonist with IC50 values of 0.6 μM for ERRα. PROTAC ERRα ligand 1 shows no significant activity against a panel of other nuclear receptors, including ERα c, ERRγ, ERβ, PPARα, PPARγ, PPARδ, and RXRα. PROTAC ERRα ligand 1 can provide enhanced insulin sensitivity in vivo. PROTAC ERRα ligand 1 can be used for metabolic diseases research, such as type 2 diabetes and obesity .
|
-
- HY-116028S1
-
|
15-Deoxy-Δ12,14-PGD2-d4
|
Isotope-Labeled Compounds
Endogenous Metabolite
Prostaglandin Receptor
PPAR
Src
|
Inflammation/Immunology
Cancer
|
|
15-Deoxy-Δ12,14-Prostaglandin D2-d4 (15-Deoxy-Δ12,14-PGD2-d4) is the deuterium labeled 15-deoxy-Δ12,14-Prostaglandin D2. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is a metabolite of prostaglandin D₂ (PGD₂) (HY-101988), which can undergo further dehydration metabolism to 15-deoxy-Δ12,14-PGJ₂. 15-deoxy-Δ12,14-Prostaglandin D2 is a highly selective agonist for DP2 receptor and PPARγ. 15-deoxy-Δ12,14-Prostaglandin D2 causes morphological changes in eosinophils and migration of type II innate lymphoid cells (ILC2). 15-deoxy-Δ12,14-Prostaglandin D2 has a growth inhibitory effect on prostate cancer cells expressing PPARγ, induces cell cycle arrest and promotes apoptosis. 15-deoxy-Δ12,14-Prostaglandin D2 can be used in related research on asthma and prostate cancer.
|
-
- HY-176243
-
|
|
Drug Derivative
Endogenous Metabolite
PPAR
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester is a derivate of 15-Deoxy-Δ-12,14-prostaglandin J2 (HY-108568). 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM .
|
-
- HY-108568S
-
|
15d-PGJ2-d4; 15-Deoxy-Δ12,14-PGJ2-d4
|
Isotope-Labeled Compounds
PPAR
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
15-Deoxy-Δ-12,14-prostaglandin J2-d4 is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM .
|
-
- HY-179015
-
|
|
17β-HSD
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
HSD17B13/PPAR modulator-1 (Compound 17) is a HSD17B13/PPAR multitarget modulator. HSD17B13/PPAR modulator-1 is an inhibitor of HSD17B13, with its IC50 value being 0.91 μM. HSD17B13/PPAR modulator-1 is a PPAR agonist, with the EC50 values for PPARα, PPARδ, and PPARγ being 1.55, 0.12, and 0.01 μM respectively. HSD17B13/PPAR modulator-1 can significantly improve liver function, regulate lipid metabolism, alleviate fibrosis, and exert antioxidant and anti-inflammatory effects in the model of metabolic dysfunction-related steatohepatitis (MASH). HSD17B13/PPAR modulator-1 can be used for the study of MASH .
|
-
- HY-116028
-
|
15-Deoxy-Δ12,14-PGD2
|
Endogenous Metabolite
Prostaglandin Receptor
PPAR
Src
|
Cardiovascular Disease
|
|
15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2), a metabolite of PGD2 (HY-101988), is an agonist of prostaglandin receptor 2 (DP2). 15-deoxy-Δ12,14-Prostaglandin D2 binds to DP2 (Ki=50 nM) and induces eosinophil activation (EC50=8 nM). 15-deoxy-Δ12,14-Prostaglandin D2 also stimulates the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), inducing PPARγ-mediated transcription. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is cytotoxic to L1210 murine leukemia cells (IC50=0.3 μg/ml) and inhibits ADP-induced platelet aggregation (IC50=320 ng/mL).
|
-
- HY-116115
-
|
17-Oxo-DPA; 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-DPA
|
NF-κB
PPAR
|
Inflammation/Immunology
|
|
17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid (17-Oxo-DPA; 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-DPA) is an electrophilic oxo-derivative (EFOX) of the docosahexaenoic acid (DHA) (HY-B2167). 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid is generated during inflammation by COX-2-catalyzed mechanism in activated macrophages. 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid acts as an agonist for PPARγ and a modulator for NF-κB signaling pathway, inhibits the production of pro-inflammatory cytokines and nitric oxide, and exhibits anti-inflammatory efficacy .
|
-
- HY-N2110
-
|
|
Akt
Sirtuin
Integrin
STAT
PI3K
Apoptosis
ERK
PPAR
PKC
Toll-like Receptor (TLR)
HIV
|
Inflammation/Immunology
|
|
Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus .
|
-
- HY-N2110R
-
|
|
Reference Standards
Akt
Sirtuin
Integrin
STAT
PI3K
Apoptosis
ERK
PPAR
PKC
Toll-like Receptor (TLR)
HIV
|
Infection
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Phellopterin (Standard) is the analytical standard of Phellopterin. Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus.
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-12557
-
|
γ-Glu-Val
|
Endogenous Metabolite
CaSR
Wnt
TNF Receptor
Interleukin Related
PPAR
β-catenin
|
Inflammation/Immunology
|
|
γ‑Glutamylvaline (γ-Glu-Val) is a calcium‑sensing receptor (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1 and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-15027
-
-
-
- HY-N0163
-
-
-
- HY-N0246
-
-
-
- HY-N0234
-
-
-
- HY-108568
-
-
-
- HY-N6641
-
-
-
- HY-N6869
-
-
-
- HY-N2025
-
-
-
- HY-N6642
-
-
-
- HY-N15574
-
-
-
- HY-N10361
-
-
-
- HY-N2110
-
|
|
Structural Classification
Classification of Application Fields
Coumarins
Phenylpropanoids
Umbelliferae
Helogyne apaloidea Nutt.
Plants
Inflammation/Immunology
Disease Research Fields
Source Classification
|
Akt
Sirtuin
Integrin
STAT
PI3K
Apoptosis
ERK
PPAR
PKC
Toll-like Receptor (TLR)
HIV
|
|
Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus .
|
-
-
- HY-U00450
-
-
-
- HY-N7043
-
-
-
- HY-N9333
-
-
-
- HY-113631
-
-
-
- HY-15027R
-
-
-
- HY-119790
-
|
|
Structural Classification
Animals
Ketones, Aldehydes, Acids
Source Classification
|
PPAR
|
|
Palmitoyllactic acid is a long-chain fatty acid with lipogenic activity. Palmitoyllactic acid can induce a brown fat-like phenotype in 3T3-L1 cells. Palmitoyllactic acid enhances the expression of a variety of brown/beige cell-specific genes, such as Prdm16 and Pgc1a. Palmitoyllactic acid acts similarly to PPARγ agonists, significantly enhancing adipogenesis in the presence of dexamethasone. Palmitoyllactic acid can be used in obesity research .
|
-
-
- HY-W341997
-
-
-
- HY-N0246R
-
-
-
- HY-13956R
-
|
U 72107 (Standard)
|
Human Gut Microbiota Metabolites
Endogenous metabolite
Source Classification
|
Reference Standards
PPAR
Ferroptosis
|
|
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
|
-
-
- HY-N7624
-
-
-
- HY-N7687
-
-
-
- HY-N0163R
-
-
-
- HY-N2110R
-
|
|
Structural Classification
Coumarins
Phenylpropanoids
Umbelliferae
Helogyne apaloidea Nutt.
Plants
Source Classification
|
Reference Standards
Akt
Sirtuin
Integrin
STAT
PI3K
Apoptosis
ERK
PPAR
PKC
Toll-like Receptor (TLR)
HIV
|
|
Phellopterin (Standard) is the analytical standard of Phellopterin. Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus.
|
-
-
- HY-N6869R
-
-
-
- HY-N2025R
-
-
-
- HY-N0234R
-
-
-
- HY-U00450R
-
-
-
- HY-N6641R
-
-
-
- HY-N7043R
-
-
-
- HY-N18020
-
-
-
- HY-127003
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-15027S1
-
|
|
|
5-Aminosalicylic acid-d3 is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
-
- HY-17386S1
-
|
|
|
Rosiglitazone-d4 is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .
|
-
-
- HY-13956S1
-
|
|
|
Pioglitazone-d4 (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .
|
-
-
- HY-17386S
-
|
|
|
Rosiglitazone-d3 is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3 .
|
-
-
- HY-B0637S
-
|
|
|
Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-143704S
-
|
|
|
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
-
- HY-15027S
-
|
|
|
5-Aminosalicylic Acid-d3 (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
|
-
-
- HY-50935S
-
|
|
|
Troglitazone-d4 is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.
|
-
-
- HY-B0205S
-
|
|
|
Candesartan-d4 (CV-11974-d4) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).
|
-
-
- HY-14728S
-
|
|
|
Deutaleglitazar (Aleglitazar-d2) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ) .
|
-
-
- HY-117727S
-
|
|
|
Leriglitazone-d4 (MIN-102-d4; Hydroxypioglitazone-d4) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .
|
-
-
- HY-15027S4
-
|
|
|
5-Aminosalicylic acid-d7 (5-ASA-d7; Mesalamie-d7; Mesalazie-d7) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .
|
-
-
- HY-108568S
-
|
|
|
15-Deoxy-Δ-12,14-prostaglandin J2-d4 is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM .
|
-
-
- HY-13956S
-
|
|
|
Pioglitazone-d4 is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .
|
-
-
- HY-B0287S
-
|
|
|
Clofibrate-d4 is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.
|
-
-
- HY-W738533
-
|
|
|
Pioglitazone-d4 hydrochloride (U 72107A-d4; AD 4833-d4) is the deuterium labeled Pioglitazone hydrochloride (HY-14601). Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
|
-
-
- HY-B0637S1
-
|
|
|
Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-B0637S2
-
|
|
|
Bezafibrate- 13C6 (BM15075- 13C6) is 13C labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-107333S
-
|
|
|
Cinoxate-d3 is deuterium labeled Cinoxate. Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity .
|
-
-
- HY-19937S1
-
|
|
|
Saroglitazar-d4 is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d4 is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
-
- HY-15027S2
-
|
|
|
5-Aminosalicylic acid- 13C6 is the 13C labeled 5-Aminosalicylic Acid . 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
|
-
-
- HY-15027S3
-
|
|
|
5-Aminosalicylic acid-d3 disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
|
-
-
- HY-W654296
-
|
|
|
Octocrylene- 13C3 is the 13C-labeled Octocrylene (HY-A0087). Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes .
|
-
-
- HY-116028S1
-
|
|
|
15-Deoxy-Δ12,14-Prostaglandin D2-d4 (15-Deoxy-Δ12,14-PGD2-d4) is the deuterium labeled 15-deoxy-Δ12,14-Prostaglandin D2. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is a metabolite of prostaglandin D₂ (PGD₂) (HY-101988), which can undergo further dehydration metabolism to 15-deoxy-Δ12,14-PGJ₂. 15-deoxy-Δ12,14-Prostaglandin D2 is a highly selective agonist for DP2 receptor and PPARγ. 15-deoxy-Δ12,14-Prostaglandin D2 causes morphological changes in eosinophils and migration of type II innate lymphoid cells (ILC2). 15-deoxy-Δ12,14-Prostaglandin D2 has a growth inhibitory effect on prostate cancer cells expressing PPARγ, induces cell cycle arrest and promotes apoptosis. 15-deoxy-Δ12,14-Prostaglandin D2 can be used in related research on asthma and prostate cancer.
|
-
-
- HY-181896S
-
|
|
|
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC50 of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-173115
-
|
|
|
Alkynes
|
|
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: